| Literature DB >> 31878256 |
Gergana G Zahmanova1,2, Milena Mazalovska1, Katerina H Takova1, Valentina T Toneva1,3, Ivan N Minkov2,3, Eugenia S Mardanova4, Nikolai V Ravin4, George P Lomonossoff5.
Abstract
The Hepatitis E virus (Entities:
Keywords: Hepatitis E virus; Influenza A M2e; chimeric HEV VLPs
Year: 2019 PMID: 31878256 PMCID: PMC7020208 DOI: 10.3390/plants9010029
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Schematic representation of the nine HEV constructs; ss–signal sequence (grey), RNA binding domain (blue), Core domain (green) and Exposed domain (yellow) containing the M2e peptide (brown) are presented as bars with different colors; 1. HEV 1–660 (full length construct); 2. HEV 33–660 (without leader sequences); 3. HEV 110–660 (N-terminal truncated); 4. HEV 1–610 (C-terminal truncated); 5. HEV 33–610 (C-terminal truncated without leader); 6. HEV 110–610 (N- and C-terminal truncated); 7. M2 HEV 1–610 (chimeric construct based on the C-terminal truncated construct); 8. M2 HEV 33–610 (chimeric construct based on the C-terminal truncated construct without leader); 9. M2 HEV 110–610 (chimeric construct based on the N- and C-terminal truncated construct).
Figure 2Transient expression of all constructs. Samples were collected day 2–11 post infiltration and analysed on SDS-PAGE gel (a) M. Molecular weight marker (kDa); 1. Leaves inoculated with the empty pEAQ-HT vector; 2–11 Protein samples extracted using TCA method from inoculated plant from day 2 pi to day 11 pi; (b) Western blot using anti-HEV ORF2 mAb, the samples are in the same order.
Figure 3(a) SDS-PAGE of HEV 110–660; M. Molecular weight marker (kDa); 1. pEAQ-HT empty vector; 2. Crude extract; 3. SN (soluble protein) after extraction in 3× volume extraction buffer and 13k rpm; 4. Pellet (insoluble part); 5. Positive control (HEV ORF2 452–617 aa recombinant protein) (b) Western blot with anti-HEV ORF2 mAb, the samples are in the same order; (c) Sucrose gradient; M. Molecular weight marker (kDa); 1. SN after pelleting; 2. Dissolved pellet from gradient; 3. 10% sucrose; 4. 20%; 5. 30%; 6. 40%; 7. 50%; 8. 60%; 9. Pellet; 10. Positive control (HEV OF2 452–617 aa recombinant protein).
Figure 4(a) SDS-PAGE gel and (b) Western blot of HEV 110–610 with anti-HEV ORF2 mAb; M. Molecular weight marker (kDa); 1. pEAQ-HT empty vector; 2. Crude extract; 3. SN (soluble protein) after extraction and spin; 4. Pellet-Insoluble part; 5. Positive control (HEV ORF2 452–617 aa recombinant protein); (c) SDS-PAGE of sucrose gradient fractions and (d) Western blot of fractions using anti-HEV ORF2 mAb; M. Molecular weight marker (kDa); 1 to 12 sucrose fractions from 10% to 60%; 13. Pellet; 14. SN after pelleting; (e) Electron microscopy of 30% (w/v) fraction and pellet.
Figure 5Schematic diagram of the chimeric M2 HEV ORF 2 capsid protein; (a) 3D modeling of M2 HEV ORF 2 capsid protein by SWISS MODEL; (b) Insertion of 24 amino acid residues of Influenza A virus M2 peptide at the position Gly556 (red) on the P domain of HEV ORF2 capsid protein.
Figure 6(a) SDS-PAGE of sucrose gradient of M2 HEV 110–610; M. Molecular weight marker (kDa); 1. TSP; 2. SN after spin the gradient; 3–10. Different sucrose fractions; 11. Pellet; (b) Western blot with anti-HEV ORF2 mAb; M. Molecular weight marker (kDa); 1. M2 HEV 110–610 supernatant 2. Fractions four to seven first were pooled and then sedimented by ultracentrifugation; (c) TEM of M2 HEV 110–610 after deliberate pelleting.
Figure 7(a) Western blot with anti-M2e mAb; M. Molecular weight marker (kDa); 1. Empty pEAQ-HT; 2. TSP extracted from M2 HEV 110–610; 3. Gradient purified M2 HEV 110–610 protein; 4. TSP extracted from HEV 110–610 crude extract; 5. HEV 110–610 after purification; (b). Western blot with anti-M2e mAb of TSP purified from different chimeric constructs; 1. M2 HEV 33–610; 2. M2 HEV 1–610; 3. M2 HEV 110–610 and 4. Empty pEAQ-HT.
Figure 8Relative efficiencies of PVX- and CPMV-based vectors; (a) Coomassie brilliant blue stained gel of 1.5 mg fresh weight (FW) and (b) Western blot of proteins isolated form N. benthamiana plants on day 4 post infiltration and separated by SDS-PAGE and analysed with anti-M2e Ab; (a) 1. Molecular weight marker (kDa); lanes 2–5, total soluble proteins isolated from zones of leaves infiltrated with agrobacteria carrying recombinant vectors pEff-HEV 110–610 (lane 2), pEff-M2 HEV 110–610 (lane 3), pEAQ-HEV 110–610 (lane 4) and pEAQ-M2 HEV 110–610 (lane 5). Lane 6 total soluble proteins isolated from noninfiltrated zone; (b) Lanes 1–3, total soluble proteins isolated from zones of leaves infiltrated with agrobacteria carrying recombinant vector pEff-M2 HEV 110–610 (lane 1), pEAQ-M2 HEV 110–610 (lane 2) and total soluble proteins isolated from noninfiltrated zone (lane 3).
Figure 9(a) SDS-PAGE of 3 mg FW; M. Molecular weight marker (kD); 1. Plant inoculated with empty pEAQ-HT; 2. TSP extracted at two dpi; 3. TSP extracted at four dpi; 4. TSP extracted at six dpi; and (b) Western blot with anti-HEV ORF2 mAb of TSP extracted from M2 HEV 110–610 at two dpi (lane 1), at four dpi (lane 2), and at six dpi (lane 3).
List of primers used in this work.
| Primer Name | Primer Sequence (5′-3′) | Purpose |
|---|---|---|
| HEV-leader F | AAATACCGGTAACA | HEV 33–660 |
| HEV-leader R | AGGCCTCGAG | HEV 33–660 |
| HEV_N110_F | AAATACCGGTAACA | HEV 110–660 |
| HEV_N33_F | AAATTCGCGAAACA | HEV 33–610, M2 HEV 33–610 |
| HEV_N33_R | CAATCTCGAG | HEV 33–610, M2 HEV 33–610 |
| HEV110_Asc-F | TAGGCGCGCC | Cloning in pEff vector |
| HEV_Sma-R | ATCCCGGGCTAAGCAAGAGCAGAGTGAGGAG | Cloning in pEff vector |